Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$264.21 USD

264.21
211,846

-1.05 (-0.40%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $264.41 +0.20 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (155 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 47.32% and 0.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?

by Zacks Equity Research

Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).

Zacks Equity Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.

Zacks Equity Research

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.

Zacks Equity Research

Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised

by Zacks Equity Research

Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.

Zacks Equity Research

Boston Scientific (BSX) Misses Q1 Earnings, Tightens EPS View

by Zacks Equity Research

Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.

Zacks Equity Research

Thermo Fisher (TMO) Beats on Q1 Earnings, Raises '19 View

by Zacks Equity Research

Thermo Fisher (TMO) reports strong Laboratory Products and Services performance, flaunting robust global demand.

Zacks Equity Research

Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise

by Zacks Equity Research

Solid demand for Accuray's (ARAY) Radixact, CyberKnife and TomoTherapy platforms continue to boost business.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.

Zacks Equity Research

Stryker (SYK) Q1 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.

Zacks Equity Research

Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.

Zacks Equity Research

Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

by Zacks Equity Research

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.

Nalak Das headshot

Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks

by Nalak Das

The U.S. labor market is the major driver of the bull run, which is more than a decade old.

Zacks Equity Research

Bio-Rad's (BIO) IH-500 System Secures 510(K) From the FDA

by Zacks Equity Research

The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.

Zacks Equity Research

Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm

by Zacks Equity Research

The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.

Zacks Equity Research

Why Is Bio-Rad (BIO) Up 12.8% Since Last Earnings Report?

by Zacks Equity Research

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Invest in Baxter International Now

by Zacks Equity Research

Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.

Zacks Equity Research

3 Reasons Why Bio-Rad (BIO) Is a Great Growth Stock

by Zacks Equity Research

Bio-Rad (BIO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st

Zacks Equity Research

Here's Why You Should Buy Masimo (MASI) Stock Right Now

by Zacks Equity Research

Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.

Zacks Equity Research

Looking for a Growth Stock? Why It is Time to Focus on Bio-Rad (BIO)

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Rad (BIO).

Zacks Equity Research

BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

by Zacks Equity Research

Becton, Dickinson (BDX) receives a number of regulatory approvals of late.

Zacks Equity Research

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) makes a few lucrative acquisitions in recent times.